Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Levothyroxine Replacement daily

Phase 1Small molecule

PPost Graduate Institute of Medical Education and Research, Chandigarh

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatic Steato-FibrosisActive, not recruiting

Hepatic Steato-FibrosisPhase 1

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Hepatic Steato-Fibrosis

NCT06373523

Clinical

Trials by Indication[1]

Hepatic Steato-Fibrosis1 trial

MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin

Active, not recruiting·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 1·NCT06373523·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Levothyroxine Replacement daily. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Levothyroxine Replacement daily compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Levothyroxine Replacement daily. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Post Graduate Institute of Medical Education and Research, Chandigarh company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPost Graduate Institute of Medical Education and Research, Chandigarh

Related News